Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.67 |
| ▸ | CTSS | P25774 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470428 | 1.00 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL1003572 | 0.88 | CTSK (0.71) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL2116924 | 0.88 | CTSK (0.71) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL26296376 | 0.87 | CTSS (0.49) | CTSKCTSSCA2PSENENMEN1 | |
| SCHEMBL16550867 | 0.87 | CTSS (0.69) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL22960908 | 0.84 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL8276584 | 0.84 | CTSK (0.70) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL16710009 | 0.84 | CTSK (0.70) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL10841914 | 0.84 | KMT2A (0.53) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28827213 | 0.84 | KMT2A (0.53) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| EP-4392417-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023025092-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023025092-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| US-5037957-A | Oliopeptides of glycine diazomethylketone and valine possibly containing proline, arginine and lucine with protective groups | GRUBB ANDERS (SE) | 1991-08-06 | — | — | US | disclosed |
| EP-0418233-A1 | CYSTEINE PROTEINASE INHIBITOR | GRUBB, Anders (SE) | 1991-03-27 | — | — | EP | disclosed |
| WO-1988010266-A1 | CYSTEINE PROTEINASE INHIBITOR | GRUBB ANDERS (SE) | 1988-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | FLT3, PHKG1, LTK | CTSK 559/4885CTSS 2523/4885CA2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.